Oxford Biodyn Share News (OBD)

Oxford BioDynamics reaches "important milestone" with new laboratory

(Alliance News) - Oxford BioDynamics PLC said on Wednesday that it has opened a clinical testing laboratory in the UK to perform EpiSwitch prostate screening tests.

TRADING UPDATES: FireAngel CFO resigns; ECR Minerals raises GBP585,000

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

CORRECT: Oxford BioDynamics plunges as annual loss widens; revenue up

(Correcting headline to show loss widened, revenue rose)

CORRECT: Oxford BioDynamics plunge as annual profit rises; revenue up

(Correcting headline to show profit and revenue rose)

Oxford BioDynamics shares plunge as annual revenue widens; revenue up

(Alliance News) - Oxford BioDynamics PLC on Wednesday said its full-year loss narrowed, but saw its revenue jump on contracts for EpiSwitch.

AIM WINNERS & LOSERS: James Cropper falls on lower outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Director dealings: Oxford Biodynamics director lowers stake

(Sharecast News) - Oxford Biodynamics revealed on Friday that Vulpes Testudo Fund had offloaded 777,000 ordinary shares in the AIM-listed biotechnology company.

IN BRIEF: Oxford BioDynamics director sells over 700,000 shares

Oxford BioDynamics PLC - biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform - Reports that Vulpes Testudo Fund, controlled by Non-Executive Director Stephen Diggle has sold 777,000 shares of one pence each at an average price of 38.3p each. Diggle is now interested in 27.6 million shares in total, through the Vulpes Testudo and Vulpes Life Sciences Funds. These represent approximately 13.62% of Oxford BioDynamics's current issued share capital. Company's market capitalisation is GBP69.79 million.

Oxford BioDynamics in deal with Bupa to expand blood test access

(Alliance News) - Oxford BioDynamics PLC shares surged on Wednesday as it announced a strategic deal with Bupa UK Insurance to enhance access to a "first-of-its-kind" blood test for cancer patients.

Oxford BioDynamics secures US billing code for prostate test

(Sharecast News) - Precision test developer Oxford BioDynamics has successfully secured a proprietary laboratory analysis (PLA) code from the American Medical Association's (AMA) Current Procedural Terminology (CPT) Editorial Board, it announced on Tuesday.

AIM WINNERS & LOSERS: Safestyle plunges as seeks cash injection

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Oxford BioDynamics issued insurance reimbursement code for EpiSwitch

(Alliance News) - Oxford BioDynamics PLC on Tuesday said it has been issued an insurance reimbursement code for its EpiSwitch product from the American Medical Association.

Oxford BioDynamics soars as validates prostate test ahead of schedule

(Alliance News) - Shares in Oxford BioDynamics PLC leapt on Tuesday after it announced the validation of its EpiSwitch prostate screening test in its US clinical laboratory was now complete, ahead of schedule.

UK shareholder meetings calendar - next 7 days